| Label-free quantification in clinical proteomics DA Megger, T Bracht, HE Meyer, B Sitek Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1834 (8), 1581-1590, 2013 | 271 | 2013 |
| Comparison of label-free and label-based strategies for proteome analysis of hepatoma cell lines DA Megger, LL Pott, M Ahrens, J Padden, T Bracht, K Kuhlmann, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844 (5), 967-976, 2014 | 143 | 2014 |
| Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study DA Megger, T Bracht, M Kohl, M Ahrens, W Naboulsi, F Weber, ... Molecular & Cellular Proteomics 12 (7), 2006-2020, 2013 | 125 | 2013 |
| Analysis of Disease-Associated Protein Expression Using Quantitative Proteomics Fibulin-5 Is Expressed in Association with Hepatic Fibrosis T Bracht, V Schweinsberg, M Trippler, M Kohl, M Ahrens, J Padden, ... Journal of proteome research 14 (5), 2278-2286, 2015 | 85 | 2015 |
| Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma J Padden, DA Megger, T Bracht, H Reis, M Ahrens, M Kohl, M Eisenacher, ... Molecular & Cellular Proteomics 13 (10), 2661-2672, 2014 | 76 | 2014 |
| Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease MM Cortese-Krott, E Mergia, CM Kramer, W Lückstädt, J Yang, G Wolff, ... Redox Biology 14, 328-337, 2018 | 72 | 2018 |
| Quantitative tissue proteomics analysis reveals versican as potential biomarker for early-stage hepatocellular carcinoma W Naboulsi, DA Megger, T Bracht, M Kohl, M Turewicz, M Eisenacher, ... Journal of proteome research 15 (1), 38-47, 2016 | 72 | 2016 |
| An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma A Lollies, S Hartmann, M Schneider, T Bracht, AL Weiss, J Arnolds, ... Leukemia 32 (1), 92-101, 2018 | 70 | 2018 |
| A practical data processing workflow for multi-OMICS projects M Kohl, DA Megger, M Trippler, H Meckel, M Ahrens, T Bracht, F Weber, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844 (1), 52-62, 2014 | 68 | 2014 |
| Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics F Großerueschkamp, T Bracht, HC Diehl, C Kuepper, M Ahrens, ... Scientific reports 7 (1), 44829, 2017 | 62 | 2017 |
| Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection J Schuhenn, TL Meister, D Todt, T Bracht, K Schork, JN Billaud, C Elsner, ... Proceedings of the National Academy of Sciences 119 (8), e2111600119, 2022 | 53 | 2022 |
| Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients T Bracht, C Mölleken, M Ahrens, G Poschmann, A Schlosser, ... Journal of Translational Medicine 14, 1-9, 2016 | 52 | 2016 |
| Integrated Fourier transform infrared imaging and proteomics for identification of a candidate histochemical biomarker in bladder cancer KE Witzke, F Großerueschkamp, H Jütte, M Horn, F Roghmann, ... The American journal of pathology 189 (3), 619-631, 2019 | 49 | 2019 |
| C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle V Kinast, A Plociennikowska, T Bracht, D Todt, RJP Brown, T Boldanova, ... Journal of hepatology 73 (3), 549-558, 2020 | 48 | 2020 |
| Systematic comparison of label-free, SILAC, and TMT techniques to study early adaption toward inhibition of EGFR signaling in the colorectal cancer cell line DiFi M Stepath, B Zülch, A Maghnouj, K Schork, M Turewicz, M Eisenacher, ... Journal of proteome research 19 (2), 926-937, 2019 | 45 | 2019 |
| Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC LL Pott, S Hagemann, H Reis, K Lorenz, T Bracht, T Herold, BV Skryabin, ... Oncotarget 8 (7), 11950, 2017 | 38 | 2017 |
| The α2β1 integrin‐specific antagonist rhodocetin is a cruciform, heterotetrameric molecule JA Eble, S Niland, T Bracht, M Mormann, J Peter-Katalinic, G Pohlentz, ... The FASEB Journal 23 (9), 2917-2927, 2009 | 37 | 2009 |
| Immunohistochemical markers distinguishing cholangiocellular carcinoma (CCC) from pancreatic ductal adenocarcinoma (PDAC) discovered by proteomic analysis of microdissected cells J Padden, M Ahrens, J Kälsch, S Bertram, DA Megger, T Bracht, ... Molecular & Cellular Proteomics 15 (3), 1072-1082, 2016 | 34 | 2016 |
| A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors H Reis, C Pütter, DA Megger, T Bracht, F Weber, AC Hoffmann, S Bertram, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1854 (6), 641-650, 2015 | 34 | 2015 |
| Deletion of Perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation A Asimakopoulou, KM Engel, N Gassler, T Bracht, B Sitek, EM Buhl, ... Cells 9 (6), 1346, 2020 | 26 | 2020 |
